The increasing prevalence of obesity and type 2 diabetes mellitus (T2DM) presents a major global health challenge, as many existing therapies lack adequate efficacy and safety. As a triple-action agonist, retatrutide enhances satiety, suppresses hunger and boosts energy expenditure, potentially providing superior benefits for blood sugar control and weight loss compared to other incretin-based therapies
Its about using this cutting-edge technology to empower lasting change, and that's a journey we're here to guide you on, every step of the way
These are typically most noticeable in the first few weeks or right after a dose change, and can include nausea, diarrhea, constipation, fatigue, and abdominal pain
This imbalance often results in rapid weight regain
With other medications, weight loss can be up to 10%
Research Applications In experimental models, retatrutide is utilized to explore metabolic signaling networks, receptor activation behavior, and integrated endocrine communication pathways
